Skip to content
1887

Journal of Medical Microbiology logo Journal of Medical Microbiology

Volume 74, Issue 4

Management of severe and fulminant infection in adults Open Access

Abstract

(formerly known as ) is a significant cause of healthcare-associated infection with symptoms ranging from diarrhoea and abdominal pain to pseudomembranous colitis and toxic megacolon. Severe disease can pose a significant morbidity and mortality risk and is to be considered a medical emergency. The emergence of a new ribotype with an estimated mortality rate of 20% (ribotype 995) has prompted a re-review of the evidence and guidelines around managing severe infections (CDI). International guidance on the management of CDI varies regarding first-line antibiotic choice. Metronidazole is no longer favoured as first line due to concerns around resistance, and vancomycin and fidaxomicin are now recommended as first line options. Antibiotic therapy should be used in conjunction with good supportive measures and early consideration of surgical management. Faecal microbiota transplant can be utilized in recurrent CDI and may be useful in severe disease. Severe CDI is a significant ongoing threat to public health, and further research into effective management is essential to ensure the best possible outcomes for patients.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): adults , C. difficile infection , Clostridioides difficile and severe
© 2025 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License.
Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.001991
2025-04-24
2025-05-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/74/4/jmm001991.html?itemId=/content/journal/jmm/10.1099/jmm.0.001991&mimeType=html&fmt=ahah

References

  1. Mada PK, Alam M, StatPearls AM. Clostridioides difficile infection; 2024 https://www.ncbi.nlm.nih.gov/books/NBK431054/ accessed 3 July 2024
  2. Abt MC, McKenney PT, Pamer EG. Clostridium difficile colitis: pathogenesis and host defence. Nat Rev Microbiol 2016; 14:609–620 [View Article] [PubMed]
     [Google Scholar]
  3. Lawley TD, Clare S, Deakin LJ, Goulding D, Yen JL et al. Use of purified Clostridium difficile spores to facilitate evaluation of health care disinfection regimens. Appl Environ Microbiol 2010; 76:6895–6900 [View Article] [PubMed]
     [Google Scholar]
  4. National Institute for Health and Care Excellence (NICE) NICE clinical knowledge summaries. Diarrhoea - antibiotic associated; 2023
  5. Ricciardi R, Rothenberger DA, Madoff RD, Baxter NN. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 2007; 142:624–631 [View Article] [PubMed]
     [Google Scholar]
  6. Kovacs-Simon A, Leuzzi R, Kasendra M, Minton N, Titball RW et al. Lipoprotein CD0873 is a novel adhesin of Clostridium difficile. J Infect Dis 2014; 210:274–284 [View Article] [PubMed]
     [Google Scholar]
  7. Carter GP, Chakravorty A, Pham Nguyen TA, Mileto S, Schreiber F et al. Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections. mBio 2015; 6:e00551 [View Article] [PubMed]
     [Google Scholar]
  8. National Institute for Health and Care Excellence (NICE) National Institute for Health and Care Excellence. Clostridium difficile infection: risk with broad-spectrum antibiotics; 2015
  9. Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections - an overview of the evidence base and challenges in data synthesis. J Glob Health 2017; 7:010417 [View Article] [PubMed]
     [Google Scholar]
  10. UK Health Security Agency. UKHSA Annual epidemiological commentary: gram-negative, MRSA, MSSA bacteraemia and C. difficile infections, up to and including financial year 2022 to 2023; 2024 https://www.gov.uk/government/statistics/mrsa-mssa-and-e-coli-bacteraemia-and-c-difficile-infection-annual-epidemiological-commentary/annual-epidemiological-commentary-gram-negative-mrsa-mssa-bacteraemia-and-c-difficile-infections-up-to-and-including-financial-year-2022-to-2023 accessed 19 August 2024
  11. McGuire E, Brown C, Islam J, Wilcox M, Planche T et al. Clostridioides difficile infection updated guidance on management and treatment. UK Health Security Agency. UKHSA; 2022 https://assets.publishing.service.gov.uk/media/6375047ee90e072854bcab13/UKHSA-CDI-guideline-july-2022_DRAFT.pdf accessed 23 September 2024
  12. Imwattana K, Knight DR, Kullin B, Collins DA, Putsathit P et al. Clostridium difficile ribotype 017 - characterization, evolution and epidemiology of the dominant strain in Asia. Emerg Microbes Infect 2019; 8:796–807 [View Article] [PubMed]
     [Google Scholar]
  13. Miller M, Gravel D, Mulvey M, Taylor G, Boyd D et al. Health care-associated Clostridium difficile infection in Canada: patient age and infecting strain type are highly predictive of severe outcome and mortality. Clin Infect Dis 2010; 50:194–201 [View Article] [PubMed]
     [Google Scholar]
  14. Office for National Statistics Deaths involving Clostridium difficile: England and Wales, 2001-2005. Health statistics quarterly / Office for National Statistics; 2007 https://webarchive.nationalarchives.gov.uk/ukgwa/20120716063931/http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-224289 accessed 10 June 2024
  15. Office for National Statistics Deaths involving Clostridium difficile: England and Wales, 1999 and 2001–06. Office for National Statistics; 2008 https://webarchive.nationalarchives.gov.uk/ukgwa/20120716063931/http://www.ons.gov.uk/ons/publications/re-reference-tables.html?edition=tcm%3A77-224289 accessed 16 June 2024
  16. Valiente E, Cairns MD, Wren BW. The Clostridium difficile PCR ribotype 027 lineage: a pathogen on the move. Clin Microbiol Infect 2014; 20:396–404 [View Article] [PubMed]
     [Google Scholar]
  17. UK Health Security Agency Emergence of new Clostridioides difficile ribotype – 955 - update. London; 2024 https://www.selondonics.org/wp-content/uploads/20240118_BN2024_003-Clostridioides-difficile-ribotype-955-Update_01.00.pdf accessed 19 August 2024
  18. McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC et al. Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis 2018; 66:e1–e48 [View Article] [PubMed]
     [Google Scholar]
  19. U.S. Centers for Disease Control and Prevention (CDC) Clinical Testing and Diagnosis for CDI; 2024
  20. Cho J, Cunningham S, Pu M, Lennon RJ, Dens Higano J et al. Clostridioides difficile whole-genome sequencing differentiates relapse with the same strain from reinfection with a new strain. Clin Infect Dis 2021; 72:806–813 [View Article] [PubMed]
     [Google Scholar]
  21. U.S. Centers for Disease Control and Prevention (CDC) United States Centers for Disease Control and Prevention C. diff (Clostridioides difficile). About C. diff 2024 https://www.cdc.gov/c-diff/about/index.html
     [Google Scholar]
  22. Lawes T, Lopez-Lozano J-M, Nebot CA, Macartney G, Subbarao-Sharma R et al. Effect of a national 4C antibiotic stewardship intervention on the clinical and molecular epidemiology of Clostridium difficile infections in a region of scotland: a non-linear time-series analysis. Lancet Infect Dis 2017; 17:194–206 [View Article] [PubMed]
     [Google Scholar]
  23. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents 2016; 48:1–10 [View Article] [PubMed]
     [Google Scholar]
  24. UKHSA and NHS England C. difficile webinar 11/12/2024 - current CDI data and trends, concerns, reporting and IPC; 2024 https://fingertips.phe.org.uk/profile/amr-local-indicators
  25. Walley T, Milson D. Loperamide related toxic megacolon in Clostridium difficile colitis. Postgrad Med J 1990; 66:582 [View Article] [PubMed]
     [Google Scholar]
  26. Cózar-Llistó A, Ramos-Martinez A, Cobo J. Clostridium difficile infection in special high-risk populations. Infect Dis Ther 2016; 5:253–269 [View Article] [PubMed]
     [Google Scholar]
  27. Eeuwijk J, Ferreira G, Yarzabal JP, Robert-Du Ry van Beest Holle M. A systematic literature review on risk factors for and timing of Clostridioides difficile infection in the United States. Infect Dis Ther 2024; 13:273–298 [View Article] [PubMed]
     [Google Scholar]
  28. Donskey CJ, Dubberke ER, Klein NP, Liles EG, Szymkowiak K et al. CLOVER (CLOstridium difficile vaccine Efficacy tRial) study: a phase 3, randomized trial investigating the efficacy and safety of a detoxified toxin A/B vaccine in adults 50 years and older at increased risk of Clostridioides difficile infection. Clin Infect Dis 2024; 79:1503–1511 [View Article] [PubMed]
     [Google Scholar]
  29. National Institute for Health and Care Excellence (NICE), Public Health England. NICE Guidance Clostridioides difficile infection: antimicrobial prescribing; 2021 https://www.nice.org.uk/guidance/ng199
  30. Department of Health, Health Protection Agency Clostridium difficile infection: how to deal with the problem. London: Department of Health; 2008
  31. Johnson S, Lavergne V, Skinner AM, Gonzales-Luna AJ, Garey KW et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults. Clin Infect Dis 2021; 73:e1029–e1044 [View Article] [PubMed]
     [Google Scholar]
  32. van Prehn J, Reigadas E, Vogelzang EH, Bouza E, Hristea A et al. European society of clinical microbiology and infectious diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27 Suppl 2:S1–S21 [View Article] [PubMed]
     [Google Scholar]
  33. Trubiano JA, Cheng AC, Korman TM, Roder C, Campbell A et al. Australasian society of infectious diseases updated guidelines for the management of Clostridium difficile infection in adults and children in australia and new zealand. Intern Med J 2016; 46:479–493 [View Article] [PubMed]
     [Google Scholar]
  34. Miller MA, Louie T, Mullane K, Weiss K, Lentnek A et al. Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy. BMC Infect Dis 2013; 13:148 [View Article] [PubMed]
     [Google Scholar]
  35. Mulherin DW, Hutchison AM, Thomas GJ, Hansen RA, Childress DT. Concordance of the SHEA-IDSA severity classification for Clostridium difficile infection and the ATLAS bedside scoring system in hospitalized adult patients. Infection 2014; 42:999–1005 [View Article] [PubMed]
     [Google Scholar]
  36. Madden GR, Petri WA Jr, Costa DVS, Warren CA, Ma JZ et al. Validation of clinical risk models for Clostridioides difficile-attributable outcomes. Antimicrob Agents Chemother 2022; 66:e0067622 [View Article] [PubMed]
     [Google Scholar]
  37. Butt E, Foster JAH, Keedwell E, Bell JEA, Titball RW et al. Derivation and validation of a simple, accurate and robust prediction rule for risk of mortality in patients with Clostridium difficile infection. BMC Infect Dis 2013; 13:316 [View Article] [PubMed]
     [Google Scholar]
  38. Napolitano LM, Edmiston CE. Clostridium difficile disease: diagnosis, pathogenesis, and treatment update. Surgery 2017; 162:325–348 [View Article]
     [Google Scholar]
  39. Sartelli M, Bella S, Khanna S, Furuya-Kanamori L, Abuzeid N et al. Update of the WSES guidelines for management of Clostridioides (Clostridium) difficile infection in surgical patients. World J Emerg Surg 2019; 14:
     [Google Scholar]
  40. United States Centers for Disease Control and Prevention United States Centers for Disease Control and Prevention C. diff (Clostridioides difficile); 2024 https://www.cdc.gov/c-diff/hcp/clinical-guidance/index.html
  41. Waqar S, Nigh K, Sisler L, Fanning M, Tancin S et al. Multidisciplinary performance improvement team for reducing health care–associated Clostridium difficile infection. Am J Infect Control 2016; 44:352–354 [View Article]
     [Google Scholar]
  42. Shivali P, Preuss Charles V, Fidelia B. StatPearls. Vancomycin; 2023 accessed 22 August 2024
  43. Gerding DN, Sambol SP, Johnson S. Non-toxigenic Clostridioides (formerly Clostridium) difficile for prevention of C. difficile infection: from bench to bedside, back to bench, and back to bedside. Front Microbiol 2018; 9:1700 [View Article] [PubMed]
     [Google Scholar]
  44. Beinortas T, Burr NE, Wilcox MH, Subramanian V. Comparative efficacy of treatments for Clostridium difficile infection: a systematic review and network meta-analysis. Lancet Infect Dis 2018; 18:1035–1044 [View Article] [PubMed]
     [Google Scholar]
  45. Fekety R, Silva J, Kauffman C, Buggy B, Gunner Deery H. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86:15–19 [View Article]
     [Google Scholar]
  46. Ereshefsky BJ, Alrahmany D, El Nekidy WS, Pontiggia L, Ghazi IM. Optimal vancomycin dose in the treatment of Clostridium difficile infection, antimicrobial stewardship initiative. J Chemother 2021; 33:165–173 [View Article] [PubMed]
     [Google Scholar]
  47. Malamood M, Nellis E, Ehrlich AC, Friedenberg FK. Vancomycin enemas as adjunctive therapy for Clostridium difficile infection. J Clin Med Res 2015; 7:422–427 [View Article] [PubMed]
     [Google Scholar]
  48. Akamine CM, Ing MB, Jackson CS, Loo LK. The efficacy of intracolonic vancomycin for severe Clostridium difficile colitis: a case series. BMC Infect Dis 2016; 16:316 [View Article] [PubMed]
     [Google Scholar]
  49. Sirbu BD, Soriano MM, Manzo C, Lum J, Gerding DN et al. Vancomycin taper and pulse regimen with careful follow-up for patients with recurrent Clostridium difficile infection. Clin Infect Dis 2017; 65:1396–1399 [View Article] [PubMed]
     [Google Scholar]
  50. Umemura T, Ota A, Mutoh Y, Norizuki C, Mizuno T et al. Efficacy of prolonged tapered and pulsed vancomycin regimen on recurrent Clostridioides difficile infection in the Japanese setting: a case control study. J Pharm Health Care Sci 2019; 5:19 [View Article] [PubMed]
     [Google Scholar]
  51. Karlowsky JA, Laing NM, Zhanel GG. In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile. Antimicrob Agents Chemother 2008; 52:4163–4165 [View Article]
     [Google Scholar]
  52. Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in europe, canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis 2012; 12:281–289 [View Article] [PubMed]
     [Google Scholar]
  53. Shaeer KM, Chahine EB, Varghese Gupta S, Cho JC. Macrolide allergic reactions. Pharmacy 2019; 7:135 [View Article]
     [Google Scholar]
  54. Gentry CA, Nguyen PK, Thind S, Kurdgelashvili G, Skrepnek GH et al. Fidaxomicin versus oral vancomycin for severe Clostridium difficile infection: a retrospective cohort study. Clin Microbiol Infect 2019; 25:987–993 [View Article] [PubMed]
     [Google Scholar]
  55. Okhuysen PC, Ramesh MS, Louie T, Kiknadze N, Torre-Cisneros J et al. A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection: clinical outcomes with microbiome and metabolome correlates of response. Clin Infect Dis 2024; 78:1462–1472 [View Article] [PubMed]
     [Google Scholar]
  56. Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364:422–431 [View Article] [PubMed]
     [Google Scholar]
  57. Guery B, Menichetti F, Anttila V-J, Adomakoh N, Aguado JM et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b/4 trial. Lancet Infect Dis 2018; 18:296–307 [View Article] [PubMed]
     [Google Scholar]
  58. Hospital Infection Control Practices Advisory Committee Recommendations for preventing the spread of vancomycin resistance. Hospital Infection Control Practices Advisory Committee (HICPAC). Emerg Infect Dis 1995; 1:1–13 [View Article] [PubMed]
     [Google Scholar]
  59. Di X, Bai N, Zhang X, Liu B, Ni W et al. A meta-analysis of metronidazole and vancomycin for the treatment of Clostridium difficile infection, stratified by disease severity. Braz J Infect Dis 2015; 19:339–349 [View Article] [PubMed]
     [Google Scholar]
  60. Nelson RL, Suda KJ, Evans CT. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Cochrane Database Syst Rev 2017; 3:CD004610 [View Article] [PubMed]
     [Google Scholar]
  61. Zar FA, Bakkanagari SR, Moorthi KMLST, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302–307 [View Article] [PubMed]
     [Google Scholar]
  62. Jump RLP, Li Y, Pultz MJ, Kypriotakis G, Donskey CJ. Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production. Antimicrob Agents Chemother 2011; 55:546–549 [View Article] [PubMed]
     [Google Scholar]
  63. Garneau JR, Valiquette L, Fortier L-C. Prevention of Clostridium difficilespore formation by sub-inhibitory concentrations of tigecycline and piperacillin/tazobactam. BMC Infect Dis 2014; 14:29 [View Article]
     [Google Scholar]
  64. Britt NS, Steed ME, Potter EM, Clough LA. Tigecycline for the treatment of severe and severe complicated Clostridium difficile infection. Infect Dis Ther 2014; 3:321–331 [View Article] [PubMed]
     [Google Scholar]
  65. Phillips EC, Warren CA, Ma JZ, Madden GR. Impact of tigecycline on C. difficile outcomes: case series and propensity-matched retrospective study. Antimicrob Agents Chemother 2022; 66:e0000122 [View Article] [PubMed]
     [Google Scholar]
  66. Zhang F, Luo W, Shi Y, Fan Z, Ji G. Should we standardize the 1,700-year-old fecal microbiota transplantation?. Am J Gastroenterol 2012; 107:1755 [View Article] [PubMed]
     [Google Scholar]
  67. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of Pseudomembranous enterocolitis. Surgery 1958; 44:854–859 [PubMed]
     [Google Scholar]
  68. Fischer M, Kao D, Mehta SR, Martin T, Dimitry J et al. Predictors of early failure after fecal microbiota transplantation for the therapy of Clostridium difficile infection: a multicenter study. Am J Gastroenterol 2016; 111:1024–1031 [View Article]
     [Google Scholar]
  69. Ma Y, Liu J, Rhodes C, Nie Y, Zhang F. Ethical issues in fecal microbiota transplantation in practice. Am J Bioeth 2017; 17:34–45 [View Article] [PubMed]
     [Google Scholar]
  70. National Institute for Health and Care Excellence. NICE guidance Faecal microbiota transplant for recurrent Clostridioides difficile infection; 2022 https://www.nice.org.uk/guidance/mtg71/chapter/5Committee-members-and-NICE-project-team accessed 10 May 2024
  71. Peery AF, Kelly CR, Kao D, Vaughn BP, Lebwohl B et al. AGA clinical practice guideline on fecal microbiota-based therapies for select gastrointestinal diseases. Gastroenterology 2024; 166:409–434 [View Article] [PubMed]
     [Google Scholar]
  72. Mullish BH, Merrick B, Quraishi MN, Bak A, Green CA et al. The use of faecal microbiota transplant as treatment for recurrent or refractory Clostridioides difficile infection and other potential indications: second edition of joint British Society of Gastroenterology (BSG) and Healthcare Infection Society (HIS) guidelines. Gut 2024; 73:1052–1075 [View Article] [PubMed]
     [Google Scholar]
  73. Hvas CL, Dahl Jørgensen SM, Jørgensen SP, Storgaard M, Lemming L et al. Fecal microbiota transplantation is superior to fidaxomicin for treatment of recurrent Clostridium difficile infection. Gastroenterology 2019; 156:1324–1332 [View Article] [PubMed]
     [Google Scholar]
  74. Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst Rev 2023; 4:CD013871 [View Article] [PubMed]
     [Google Scholar]
  75. Cammarota G, Ianiro G, Tilg H, Rajilić-Stojanović M, Kump P et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66:569–580 [View Article] [PubMed]
     [Google Scholar]
  76. Wilcox MH, Ahir H, Coia JE, Dodgson A, Hopkins S et al. Impact of recurrent Clostridium difficile infection: hospitalization and patient quality of life. Antimicrob Agents Chemother 2017; 72:2647–2656 [View Article]
     [Google Scholar]
  77. Cho JC, Crotty MP, Pardo J. Ridinilazole: a novel antimicrobial for Clostridium difficile infection. Ann Gastroenterol 2019; 32:134–140 [View Article] [PubMed]
     [Google Scholar]
  78. Snydman DR, McDermott LA, Thorpe CM, Goldstein EJC, Schuetz AN et al. A US-based national surveillance study for the susceptibility and epidemiology of Clostridioides difficile isolates with special reference to ridinilazole: 2020-2021. Antimicrob Agents Chemother 2023; 67:e0034923 [View Article] [PubMed]
     [Google Scholar]
  79. Vickers R, Robinson N, Best E, Echols R, Tillotson G et al. A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections. BMC Infect Dis 2015; 15:91 [View Article] [PubMed]
     [Google Scholar]
  80. Viscidi R, Laughon BE, Yolken R, Bo-Linn P, Moench T et al. Serum antibody response to toxins A and B of Clostridium difficile. J Infect Dis 1983; 148:93–100 [View Article] [PubMed]
     [Google Scholar]
  81. Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66:2018–2025 [View Article] [PubMed]
     [Google Scholar]
  82. Katchar K, Taylor CP, Tummala S, Chen X, Sheikh J et al. Association between IgG2 and IgG3 subclass responses to toxin A and recurrent Clostridium difficile-associated disease. Clin Gastroenterol Hepatol 2007; 5:707–713 [View Article] [PubMed]
     [Google Scholar]
  83. Abougergi MS, Kwon JH. Intravenous immunoglobulin for the treatment of Clostridium difficile infection: a review. Dig Dis Sci 2011; 56:19–26 [View Article] [PubMed]
     [Google Scholar]
  84. Negm OH, MacKenzie B, Hamed MR, Ahmad OAJ, Shone CC et al. Protective antibodies against Clostridium difficile are present in intravenous immunoglobulin and are retained in humans following its administration. Clin Exp Immunol 2017; 188:437–443 [View Article] [PubMed]
     [Google Scholar]
  85. Koo HL, DuPont HL. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gastroenterol 2010; 26:17–25 [View Article] [PubMed]
     [Google Scholar]
  86. Reigadas E, Muñoz-Pacheco P, Vázquez-Cuesta S, Alcalá L, Marín M et al. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients. Anaerobe 2017; 48:269–272 [View Article]
     [Google Scholar]
  87. Ng QX, Loke W, Foo NX, Mo Y, Yeo W-S et al. A systematic review of the use of rifaximin for Clostridium difficile infections. Anaerobe 2019; 55:35–39 [View Article] [PubMed]
     [Google Scholar]
  88. Louie T, Golan Y, Khanna S, Bobilev D, Erpelding N et al. VE303, a defined bacterial consortium, for prevention of recurrent Clostridioides difficile infection: a randomized clinical trial. JAMA 2023; 329:1356–1366 [View Article] [PubMed]
     [Google Scholar]
  89. Goldenberg JZ, Yap C, Lytvyn L, Lo CK-F, Beardsley J et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev 2017; 12:CD006095 [View Article] [PubMed]
     [Google Scholar]
  90. Byrn JC, Maun DC, Gingold DS, Baril DT, Ozao JJ et al. Predictors of mortality after colectomy for fulminant Clostridium difficile colitis. Arch Surg 2008; 143:150–154 [View Article] [PubMed]
     [Google Scholar]
  91. Richards SJG, Frizelle FA, Geddes JA, Eglinton TW, Hampton MB. Frailty in surgical patients. Int J Colorectal Dis 2018; 33:1657–1666 [View Article] [PubMed]
     [Google Scholar]
  92. Girotra M, Kumar V, Khan J, Damisse P, Abraham R et al. Clinical predictors of fulminant colitis in patients with Clostridium difficile infection. Saudi J Gastroenterol 2012; 18:133 [View Article]
     [Google Scholar]
  93. Ferrada P, Callcut R, Zielinski MD, Bruns B, Yeh DD et al. Loop ileostomy versus total colectomy as surgical treatment for Clostridium difficile - associated disease: an eastern association for the surgery of trauma multicenter trial. J Trauma Acute Care Surg 2017; 83:36–40 [View Article] [PubMed]
     [Google Scholar]
  94. Felsenreich DM, Gachabayov M, Rojas A, Latifi R, Bergamaschi R. Meta-analysis of postoperative mortality and morbidity after total abdominal colectomy versus loop ileostomy with colonic lavage for fulminant Clostridium difficile colitis. Dis Colon Rectum 2020; 63:1317–1326 [View Article]
     [Google Scholar]
  95. Abou-Khalil M, Garfinkle R, Alqahtani M, Morin N, Vasilevsky CA et al. Diverting loop ileostomy versus total abdominal colectomy for Clostridioides difficile colitis: outcomes beyond the index admission. Surg Endosc 2021; 35:3147–3153 [View Article]
     [Google Scholar]
  96. Bhangu A, Nepogodiev D, Gupta A, Torrance A, Singh P et al. Systematic review and meta-analysis of outcomes following emergency surgery for Clostridium difficile colitis. Br J Surg 2012; 99:1501–1513 [View Article] [PubMed]
     [Google Scholar]
/content/journal/jmm/10.1099/jmm.0.001991
Loading
Management of severe and fulminant Clostridioides difficile infection in adults
J. Med. Microbiol. 74, 001991 (2025); https://doi.org/10.1099/jmm.0.001991
/content/journal/jmm/10.1099/jmm.0.001991
/content/journal/jmm/10.1099/jmm.0.001991
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error